| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in china, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [2] |
Oupret M, Babjuk M, comperat E, et a1. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update[J]. Eur Urol, 2018, 73(1): 111-122.
|
| [3] |
方冬，黄吉炜，鲍一歌, 等. 中国上尿路尿路上皮癌人群特征和地区差异:基于CUDA-UTUC协作组的多中心研究[J]. 中华泌尿外科杂志, 2017, 38(2): 885-890.
|
| [4] |
Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration [J]. Cancer, 2009, 115(6): 1224-1233.
|
| [5] |
Cummings KB. Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract [J]. Urol Clin North Am, 1980, 7(3): 569-578.
|
| [6] |
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer[J]. N Engl J Med, 2003, 349(9): 859-866.
|
| [7] |
Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma[J]. Cancer, 2010, 116(13):3127-3134.
|
| [8] |
Liao RS, Gupta M, Schwen ZR, et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma[J]. J Urol, 2018, 200(1): 68-73.
|
| [9] |
Foerster B, Abufaraj M, Petros F, et al. Efficacy of preoperative chemotherapy in high-risk upper tract urothelial carcinoma (UTUC)[J]. J Urol, 2020, 203(6): 101097
|
| [10] |
Porten, S, Siefker-Radtke AO, Xiao L, et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma[J]. Cancer, 2014, 120(12): 1794-1799.
|
| [11] |
Koie T, Ohyama C, Fujimoto H, et al. Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association[J]. Jpn J Clin Oncol, 2016, 46(5): 468-474.
|
| [12] |
Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration[J]. Cancer, 2009, 115(6): 1224-1233.
|
| [13] |
Favaretto RL, Shariat SF, Chade DC, et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?[J]. Eur Urol, 2010, 58(5): 645-651.
|
| [14] |
Ni S1, Tao W, Chen Q, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies[J]. Eur Urol, 2012, 61(6): 1142-1153.
|
| [15] |
Simone G, Papalia R, Guaglianone S, et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study[J]. Eur Urol, 2009, 56(3): 520-526.
|
| [16] |
Aboumohamed AA, Krane LS, Hemal AK. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma[J]. J Urol, 2015, 194(6): 1561-1566.
|
| [17] |
Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the eau nonmuscle invasive bladder cancer guidelines panel[J]. Eur Urol, 2016, 70(6): 1052-1068.
|
| [18] |
Zareba P, Rosenzweig B, Winer AG, et al. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract[J]. Cancer, 2017, 123(10): 1741-1750.
|
| [19] |
Dominguez-Escrig JL, Peyronnet B, Seisen T, et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the european association of urology guidelines panel on non-muscle-invasive bladder cancer[J]. Eur Urol Focus, 2017, 5(2): 224-241.
|
| [20] |
O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol, 2011, 60(4): 703-710.
|
| [21] |
Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial[J]. J Clin Oncol, 2013, 31(11): 1422-1427.
|
| [22] |
梁华民，齐文旭，张明. 上尿路尿路上皮癌手术后单次与多次膀胱灌注化疗对发生膀胱癌的影响[J]. 中国药物与临床2019, 19(5): 74-756
|
| [23] |
Czito B, Zietman A, Kaufman D, et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter[J]. J Urol, 2004, 172(4 Pt 1): 1271-1275.
|
| [24] |
Seisen T, Krasnow RE, Bellmunt J, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma[J]. J Clin Oncol, 2017, 35(8): 852-860.
|
| [25] |
Birtle, AJ, Chester, JD, Jones RJ, et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) [J]. J Clin Oncol, 2018, 36 (6_suppl): 407.
|